Approved October 2006
External genital and perianal warts
Veregen (kunecatechins) 15% is a botanical drug product for topical use. It is comprised of kunecatechins, which is a partially purified fraction of the water extract of green tea leaves, and is a mixture of catechins and other green tea components. Catechins are bioflavonoids, polyphenols and powerful anti-oxidants and are linked to to evidence of fighting tumors as well as enhancing immune system function.
Veregen is specifically indicated for the topical treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older.
Veregen is supplied as an ointment for topical administration. The recommended initial dose of the drug is a 0.5 cm strand applied in a thin layer over all external and perianal warts, three times a day. Treatment should not exceed 16 weeks.
FDA approval of Veregen was based on the pooled results of two randomized, double-blind, vehicle-controlled phase III clinical trials. These trials enrolled a combined 1,000 immunocompetent subjects who received the ointment three times daily for up to 16 weeks or until complete clearance of all warts. The primary endpoint was the response rate defined as the proportion of patients with complete clinical (visual) clearance of all external genital and perianal warts (baseline and new) by week 16. Of the subjects treated with Veregen, 53.6% reached complete clearance versus 35.3% on placebo. The median time to complete wart clearance was 16 weeks and 10 weeks, respectively, in the two trials.
Ongoing Study Commitments
Adverse events associated with the use of Veregen may include, but are not limited to, the following:
Veregen is a botanical drug product for topical use. The drug substance in Veregen is Kunecatechins, which is a partially purified fraction of the water extract of green tea leaves from Camellia sinensis O Kuntze, and is a mixture of catechins and other green tea components. While the exact mechanism of action of catechins is unknown, they are powerful anti-oxidants and are linked to to evidence of fighting tumors as well as enhancing immune system function.
The Veregen (kunecatechins) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.